Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy
- PMID: 21281877
- DOI: 10.1016/j.jaci.2010.10.055
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy
Comment on
-
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.J Allergy Clin Immunol. 2010 Feb;125(2):383-9. doi: 10.1016/j.jaci.2009.11.022. J Allergy Clin Immunol. 2010. PMID: 20159249 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
